<DOC>
	<DOCNO>NCT01497717</DOCNO>
	<brief_summary>Hypothesis - Behcet 's disease multisystemic chronic relapse inflammatory disease , classify among vasculitides . The clinical manifestation include mucocutaneous lesion , articular , ocular , vascular , gastrointestinal and/or central nervous system involvement . The aetiology Behcet 's disease unknown , however . Experimental evidence suggest TNF-α may play important role pathogenesis disease . To date , case report small open-short term study report efficacy anti-TNFα therapy ( Infliximab Etanercept ) , especially regard ocular mucocutaneous involvement Behcet . There double blind long term study large number patient regard efficacy anti-TNFα , especially Humira heal arthritis +/- manifestation disease .</brief_summary>
	<brief_title>Efficacy Humira Behcet Patients With Arthritis</brief_title>
	<detailed_description>Study Design ( include visit schedule , dose procedures/methods ) : Screen visit , 1st visit -treatment initiation , follow-up visit - 1 month afterwards every 8 week 24 week . Screen visit : informed consent , medical history , inclusion exclusion criterion , pregnancy test , vital sign , physical examination , joint evaluation ( . tender joint , . swollen joint ) , patient/investigator global disease activity , pain VAS , HAQ , Behcet Disease Current Activity Forms ( BDACF ) , ECG , PPD chest X-ray screening tuberculosis , routine lab ( performed local HMO routine follow-up patient treatment DMARD 's ) : CBC , blood chemistry , ESR , CRP , urinalysis , HbsAg AntiHCV , immunology lab ( rheumatoid factor , anti-CCP , anti nuclear antibody - ANA ) . An induration great 5 mm consider positive PPD reaction . Follow visit . : Vital sign , joint evaluation , patient/investigator global disease activity , pain VAS , HAQ , BDACF , routine lab ( performed local HMO routine follow-up patient treatment DMARD 's ) : CBC , blood chemistry , ESR , CRP , urinalysis , research blood sample storage .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Able willing give write informed consent comply requirement study protocol . 2 . Patients Behcet disease , fulfil International Study group criterion Behcet Disease . 3 . Experienced inadequate response previous current treatment one DMARDs inadequate efficacy side effect . 4 . DMARDS and/or corticosteroid ( &lt; equivalent 10mg/d prednisone ) permit stable least 4 week prior screen . NSAIDs permit stable least 2 week prior screen . 5 . Active peripheral arthritis screening ( tenderness swell least 3 small joint one large joint ) OR axial involvement ( active enthesitis spondylitis ) 6 . Age 1880 year . 7 . If female childbearing potential , negative urine pregnancy test within 2 week prior therapy , use reliable mean contraception . 1 . Rheumatic autoimmune disease Behcet ( Rheumatoid arthritis , SLE , scleroderma , etc ) . 2 . Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine gastrointestinal disorder . 3 . Known active bacterial , viral , fungal , mycobacterial infection , major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week prior screen . 4 . History lymphoproliferative hematologic malignancy . History type cancer past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>